M&A / Deals Novartis and Chai Discovery collaborate on antibody identification Pharmaceutical TechnologyNovartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.Read full story pharminent July 14, 2026 (Last updated: July 14, 2026) Pharmaceutical Technology Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Mahzi Lets Rare-Disease Families Invest in Its Gene TherapyNext: Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
